Raynaud's: Labs, Diagnosis, and Next Steps

What Is Raynaud's Phenomenon?

Raynaud's phenomenon is episodic vasospasm of the digital arteries, producing the classic white-blue-red color sequence in fingers or toes when exposed to cold temperatures or emotional stress. The underlying mechanism involves exaggerated vascular smooth-muscle contraction combined with endothelial dysfunction and altered neural control of blood flow [1].

The condition splits into two categories. Primary Raynaud's (previously called Raynaud's disease) occurs without any detectable underlying pathology and accounts for the large majority of cases. Secondary Raynaud's (Raynaud's phenomenon) is linked to connective tissue diseases, vascular disorders, medications, or occupational exposures. A 2015 meta-analysis published in the Journal of the American Heart Association estimated global prevalence at 3-5%, with higher rates in colder climates [2]. Women are affected far more often than men. The female predominance is especially pronounced in the primary form, where the ratio approaches 9:1 [1].

Distinguishing primary from secondary matters because secondary Raynaud's carries risks of digital ischemia, tissue loss, and progression of the underlying autoimmune condition. The following sections outline exactly which labs to order, what results mean, and what treatment steps to take based on findings.

Why Does Raynaud's Happen? Root Causes Explained

The short answer: an exaggerated vasoconstrictive response. In primary Raynaud's, the problem is functional, not structural. Cold exposure triggers alpha-2 adrenergic receptor activation in digital arteries, and patients with Raynaud's have a lower threshold for this response [3].

Secondary Raynaud's has identifiable causes. The most common is systemic sclerosis (scleroderma), where structural vascular damage and fibrosis produce fixed narrowing of digital arteries. A landmark cohort study from the European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) database found that Raynaud's preceded other scleroderma symptoms by a median of 4.8 years in 95% of patients [4]. Other autoimmune conditions linked to secondary Raynaud's include systemic lupus erythematosus (SLE), mixed connective tissue disease, Sjögren's syndrome, and dermatomyositis [1].

Non-autoimmune causes deserve attention too. These include:

• Medications: beta-blockers, ergotamine, certain chemotherapy agents (bleomycin, cisplatin), and stimulants like amphetamines
• Occupational exposures: vibration injury (hand-arm vibration syndrome), vinyl chloride exposure
• Vascular conditions: thoracic outlet syndrome, atherosclerosis, thromboangiitis obliterans (Buerger's disease)
• Hematologic disorders: cryoglobulinemia, cold agglutinin disease, polycythemia vera

The 2022 American College of Rheumatology (ACR) guidelines note that "medication history and occupational exposure assessment should precede any laboratory investigation" in Raynaud's workup [5]. This is a practical point. Stopping an offending drug may resolve symptoms entirely.

The Diagnostic Workup: Which Labs to Order

A structured lab panel separates primary from secondary Raynaud's with high confidence. The 2017 BMJ Best Practice guidelines recommend a tiered approach [6].

First-tier labs (order for every patient with Raynaud's):

• Antinuclear antibody (ANA): The single most important screening test. A negative ANA at 1:40 dilution has a negative predictive value exceeding 95% for ruling out systemic sclerosis [7]. A positive ANA warrants reflex testing for specific antibodies.
• Complete blood count (CBC): Screens for hematologic causes including polycythemia, cryoglobulinemia, and cold agglutinin disease.
• Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP): Nonspecific inflammatory markers that, when elevated, push the diagnosis toward secondary causes.
• Comprehensive metabolic panel (CMP): Evaluates renal function and screens for hepatic involvement.
• Thyroid-stimulating hormone (TSH): Hypothyroidism can worsen Raynaud's symptoms and is easily treated.

Second-tier labs (order when ANA is positive or clinical suspicion is high):

• Anti-centromere antibodies (ACA): Strongly associated with limited cutaneous systemic sclerosis (CREST syndrome). Present in 50-90% of limited SSc patients [7].
• Anti-Scl-70 (anti-topoisomerase I): Associated with diffuse cutaneous systemic sclerosis and interstitial lung disease.
• Anti-RNA polymerase III: Linked to diffuse SSc with renal crisis risk.
• Anti-dsDNA and anti-Smith: Specific for SLE.
• Complement levels (C3, C4): Low levels suggest active lupus or cryoglobulinemia.
• Cryoglobulins: Order if symptoms worsen with cold exposure beyond typical Raynaud's patterns, especially with purpura or arthralgia.
• Anti-SSA/SSB (Ro/La): Screens for Sjögren's syndrome.

Dr. Fredrick Wigley of Johns Hopkins, a leading authority on Raynaud's research, has stated: "The combination of a positive ANA, abnormal nailfold capillaries, and Raynaud's-specific autoantibodies identifies patients at highest risk for progression to a defined connective tissue disease within five years" [8].

Nailfold Capillaroscopy: The Test Most Doctors Skip

Nailfold capillaroscopy is the most underused and arguably most informative test in the Raynaud's workup. It provides direct visualization of the capillary loops at the base of the fingernail using a dermatoscope or specialized microscope. This is non-invasive, takes under five minutes, and costs less than most blood panels.

The EULAR/European Dermatology Forum guidelines give nailfold capillaroscopy a Grade A recommendation for differentiating primary from secondary Raynaud's [9]. Normal capillaries appear as uniform hairpin loops. In secondary Raynaud's associated with scleroderma-spectrum diseases, three abnormal patterns emerge: enlarged capillaries (early), capillary loss with avascular areas (active), and disorganized architecture with neovascularization (late) [9].

A prospective study published in Arthritis & Rheumatism followed 586 patients presenting with Raynaud's for a mean of 4.7 years. Among those with both a positive ANA and abnormal capillaroscopy, 79.5% progressed to a defined connective tissue disease. Among those with normal capillaroscopy and negative ANA, the progression rate was only 1.8% [10]. That degree of predictive separation makes the combination of ANA plus capillaroscopy one of the most powerful screening dyads in rheumatology.

The problem is access. Many primary care offices lack a capillaroscope, and referral to rheumatology for the test can take months. An ophthalmoscope set to +40 diopters provides a reasonable alternative, though image quality is lower. The ACR's 2022 position paper acknowledges that "telemedicine-based capillaroscopy using smartphone attachments may expand access in underserved areas" [5].

When Should You Worry? Red Flags That Demand Action

Not all Raynaud's is benign. Specific clinical features should trigger urgent evaluation and referral to rheumatology.

High-concern findings include:

• Digital ulcers or pitting scars: These indicate structural vascular disease, not just vasospasm. In the EUSTAR cohort, 43% of scleroderma patients developed digital ulcers, with a recurrence rate of 66% within two years [4].
• Asymmetric episodes: Primary Raynaud's is symmetric. Unilateral or asymmetric involvement suggests local vascular pathology (thoracic outlet syndrome, emboli, or vasculitis).
• Onset after age 40: Primary Raynaud's typically presents before age 30. Late onset raises suspicion for secondary causes, particularly malignancy-associated Raynaud's.
• Abnormal Allen test: A prolonged capillary refill on Allen testing suggests fixed arterial obstruction rather than reversible vasospasm.
• Constitutional symptoms: Unexplained weight loss, joint pain, skin thickening, dysphagia, or fatigue alongside Raynaud's points toward systemic autoimmune disease.

The 2017 BMJ Best Practice guidelines define the "scleroderma pattern" as the triad of Raynaud's, positive ANA, and abnormal nailfold capillaroscopy, and recommend these patients be followed at 6-month intervals even if they do not yet meet classification criteria for a specific connective tissue disease [6].

Treatment: From Lifestyle Changes to Prescription Options

Treatment follows a stepwise approach based on severity and whether the Raynaud's is primary or secondary.

Step 1: Non-pharmacologic measures (all patients). Cold avoidance is the foundation. This means whole-body warming, not just gloves. Core body temperature drives digital perfusion more than hand covering alone. Smoking cessation is mandatory, as nicotine is a potent vasoconstrictor. A Cochrane review confirmed that behavioral interventions including biofeedback and temperature-feedback training produced modest but statistically significant reductions in attack frequency [11].

Step 2: First-line pharmacotherapy. Dihydropyridine calcium channel blockers remain the standard. Nifedipine extended-release 30-60 mg daily is the most studied agent. A Cochrane meta-analysis of 7 RCTs (N=296) found nifedipine reduced attack frequency by approximately 33% and attack severity by 33% compared to placebo [12]. Amlodipine 5-10 mg daily is an alternative with a more favorable side-effect profile. The 2022 ACR conditional recommendation supports CCBs as first-line pharmacotherapy [5].

Step 3: Second-line agents for refractory disease.

• Phosphodiesterase-5 inhibitors: Sildenafil 20 mg three times daily showed benefit in a meta-analysis of 6 RCTs (N=244), reducing attack frequency by 0.49 attacks per day and improving digital blood flow [13].
• Topical nitrates: Nitroglycerin 0.2% ointment applied to affected digits can provide local vasodilation. A randomized trial (N=33) showed improvement in blood flow measured by laser Doppler [1].
• Fluoxetine: The selective serotonin reuptake inhibitor at 20 mg daily reduced attack frequency and severity in a small crossover trial. This option is particularly useful when Raynaud's coexists with depression or anxiety [1].

Step 4: Severe or secondary Raynaud's with digital ischemia.

• Iloprost (IV prostacyclin): The European standard for digital ulcer healing. A key RCT showed that IV iloprost (0.5-2 ng/kg/min for 5 days) healed digital ulcers in 34.8% of scleroderma patients vs. 19.4% with placebo [14].
• Bosentan: The endothelin receptor antagonist is FDA-approved for prevention of new digital ulcers in scleroderma. The RAPIDS-2 trial (N=188) demonstrated a 30% reduction in new ulcer formation over 24 weeks compared to placebo [15].
• Botulinum toxin A: Periarterial injection in the hand showed promising results in case series, though RCT data remain limited [1].

Building Your Action Plan: Practical Next Steps

A clear decision tree helps determine what to do after a Raynaud's diagnosis. The 2022 ACR and EULAR guidelines converge on this approach [5][9].

If your labs are completely normal (negative ANA, normal CBC/ESR/CRP, normal capillaroscopy): You have primary Raynaud's. The probability of developing an underlying connective tissue disease is under 2% over 5 years [10]. Treatment focuses on cold avoidance, behavioral strategies, and CCBs if attacks are frequent or disabling. Annual follow-up is reasonable but intensive monitoring is not needed.

If ANA is positive but capillaroscopy is normal and you have no other symptoms: You are in an intermediate-risk category. The EULAR recommendation is clinical follow-up every 6-12 months with repeat capillaroscopy and symptom assessment [9]. No autoimmune-specific treatment is indicated at this stage.

If ANA is positive and capillaroscopy is abnormal: Your 5-year risk of progressing to a defined connective tissue disease approaches 80% [10]. Referral to rheumatology is essential. Baseline testing should include pulmonary function tests (to screen for interstitial lung disease), echocardiography (to screen for pulmonary arterial hypertension), and specific autoantibody profiling.

Dr. Ariane Herrick of the University of Manchester, writing in The Lancet, noted: "Early identification of the scleroderma pattern of microangiopathy allows therapeutic intervention before irreversible organ damage occurs" [16]. This underscores why the lab workup matters. Catching secondary Raynaud's early changes outcomes.

If you have digital ulcers or critical ischemia: Seek same-week rheumatology or vascular surgery evaluation. IV iloprost or bosentan should be considered without delay. Digital sympathectomy is a surgical option for refractory ischemia.

Tracking your attacks in a symptom diary (noting triggers, duration, and number of digits involved) provides objective data that guides treatment intensity at follow-up visits. The Raynaud's Condition Score, a validated daily self-assessment scale from 0-10, gives clinicians a standardized outcome measure to track response to therapy [12].